To be announced.
CTSS and DDTSS Webinar: Artificial Intelligence in the Design of Safer Medicines—Science or Science Fiction
Thursday, June 25, 2020 11:00 am Eastern Daylight Time (New York, GMT – 4:00)
Artificial Intelligence in the Design of Safer Medicines—Science or Science Fiction?
There are strong economic drivers to reduce the costs associated with the discovery of new medicines. However, drug discovery and development are multiparameter optimization problems that require a novel medicine to have a fine balance between its efficacy, ADME properties and safety. Although the number of clinical failures from safety has been reduced in recent years, there are still improvements that could be made. Data science and artificial intelligence is a potential method to both improve the safety profile of new drugs as well as reduce the costs and time to bring these to the clinic. This talk will highlight some of the current investments in computational methods and highlight some of the key gaps in realizing these benefits.
Nigel Greene, PhD, Director, Imaging and Data Analytics, Clinical Pharmacology & Safety Sciences, AstraZeneca
Intro Slides | Webinar Recording
DDTSS Webinar: Nonclinical Safety Strategies for Gene Therapy
Tuesday, February 25, 2020 11:00 am Eastern Standard Time (New York, GMT–05:00)
Gene therapy has been a hot topic these recent years, with the first approvals allowing patients to be successfully treated. This increased interest in gene therapy resulted in a lot of potential therapies in preclinical and clinical development.
This webinar will cover the basis of what gene therapy is and the main toxicology concerns and considerations that need to be investigated when developing a nonclinical safety package.
Timothy Maclachlan, Executive Director, PCS TA Head, New Indications Discovery Unit, Novartis
Kelly Flagella, Executive Director Toxicology at Ultragenix
DDTSS Webinar: Lead Optimization Drug Safety Strategies for Small Molecules
Monday, October 29, 2018 at 11 am Eastern Daylight Time (New York, GMT–04:00)
Panelists, Zoe Zhong, PhD, DABT (Associate Director, Head of Small Molecule Discovery Toxicology at Genentech) and Mark Fielden, PhD, DABT (Scientific Director, Comparative Biology and Safety Sciences at Amgen), will provide insights on lead optimization strategies to increase selectivity, minimize off-target effects, and integrate assessments of in vitro and in vivo toxicology studies for rapid identification of clinical candidates. The intended audience is scientists across all career stages interested in deepening their knowledge of drug discovery.
Presentation by Zoe Zhong | Presentation by Mark Fielden | Webinar Recording
DDTSS Webinar: Careers and Opportunities in Pharmaceutical Discovery Toxicology
Wednesday, April 5, 2017 11:00 am Eastern Daylight Time (New York, GMT–04:00)
This unique 90-minute webinar comprises two distinct presentations in which experts will discuss career development in the pharmaceutical drug discovery space.
Presentation by Dolo Diaz | Presentation by Brandon Jeffy | Webinar Recording
Specific topics each speaker will discuss include:
Personal experience and career path development (how did they get here?)
How does discovery tox function at your current place of employment (e.g. startup biotech vs. larger pharma)?
What skills did you learn in grad school/postdoc that you could apply to your position in drug discovery?
How did those skills and responsibilities change over time with varying levels of experience e.g. from starting at a junior position to increasing responsibilities, what did career progression look like (designing/running studies, sitting on project teams, portfolio oversight etc.)?
Any sort of anecdotes/personal experiences to illustrate variety of paths and career progression in drug discovery tox?
Comments/examples on “I vs. we” approach or comparison of individual role vs. team responsibilities in pharmaceutical industry.
We plan on a 5 minute intro from our president Ray Kemper, followed by a 20–25 minute presentation from each of the 2 speakers, with time for questions at the end.
DDTSS Webinar: Safety Assessment in a World of Expanding Immuno-oncology Approaches
Tuesday, January 24, 2017 11:00 am Eastern Standard Time (New York, GMT–05:00)
No Recording is available for this Webinar.
This unique 90-minute webinar comprises three distinct presentations in which experts will discuss safety assessment in the growing field of immuno-oncology research.
Nonclinical Safety Assessment of Checkpoint Inhibitors and Costimulatory Agonists
The harnessing of the immune system to fight cancer is becoming a reality with the approval of several therapeutics that are transforming the way cancer is being treated. This presentation will discuss key considerations and challenges in the nonclinical safety assessment of checkpoint inhibitors and costimulatory agonistic monoclonal antibodies and approaches to enhance the value of preclinical models by incorporating biomarkers of immune activation to help understand the relevance of the model, immunologic activities and toxicities, and define the clinical stating dose.
Evolution of Safety Assessment for T Cell-Dependent Bispecific Molecules
The advent of molecules that redirect the T cell killing machinery to tumors has expanded the cancer immunotherapy repertoire. These molecules are highly potent and rapidly activate T cells upon antigen recognition. As a result the nonclinical safety assessment of T cell engaging bispecific molecules has had to evolve from the traditional approach. This webinar will discuss some of the novel challenges and strategies taken in the nonclinical safety assessment of T cell engaging bispecific molecules.
Safety Assessment of Immune Cell-Based Therapies for Immuno-Oncology
Evasion of immune surveillance represents a major mechanism limiting the effectiveness of traditional therapies against tumor cells. An increasing number of approaches designed to stimulate or directly utilize the immune system in overcoming this limitation are currently undergoing preclinical and clinical testing, including immunotherapies utilizing auto reactive effector cells. One significant factor potentially limiting the widespread use of T cell therapies for a variety of cancer types includes the expression of target antigens on cancer cells as well as on other normal, and essential, tissues. This presentation will review the field of adoptive T cell therapies as well as current thinking concerning nonclinical safety assessment approaches for such therapies.